146 related articles for article (PubMed ID: 30883687)
1. Presence of anti-BP180 and anti-BP230 in the cerebrospinal fluid of patients with bullous pemphigoid and neurological disease: is there any intrathecal synthesis?
Meudec L; Amode R; Brunet-Possenti F; Mignot S; Descamps V
Br J Dermatol; 2019 Oct; 181(4):828-829. PubMed ID: 30883687
[No Abstract] [Full Text] [Related]
2. A possible association between BP230-type bullous pemphigoid and dementia: a report of two cases in elderly patients.
Zheng M; Ujiie H; Muramatsu K; Sato-Matsumura KC; Maeda T; Ujiie I; Iwata H; Izumi K; Nishie W; Shimizu H
Br J Dermatol; 2018 Jun; 178(6):1449-1450. PubMed ID: 29278417
[No Abstract] [Full Text] [Related]
3. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
Julio TA; Vernal S; Massaro JD; Silva MC; Donadi EA; Moriguti JC; Roselino AM
Immunol Res; 2018 Oct; 66(5):567-576. PubMed ID: 30220011
[TBL] [Abstract][Full Text] [Related]
4. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
[No Abstract] [Full Text] [Related]
6. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
7. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
[TBL] [Abstract][Full Text] [Related]
8. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
[TBL] [Abstract][Full Text] [Related]
10. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
12. Role of BP230 autoantibodies in bullous pemphigoid.
Shih YC; Wang B; Yuan H; Zheng J; Pan M
J Dermatol; 2020 Apr; 47(4):317-326. PubMed ID: 32048350
[TBL] [Abstract][Full Text] [Related]
13. Bullous Pemphigoid and Neurologic Diseases: Toward a Specific Serologic Profile?
Petrera MR; Tampoia M; Guida S; Abbracciavento L; Fumarulo R; Foti C
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):662-664. PubMed ID: 30062977
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
[TBL] [Abstract][Full Text] [Related]
15. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
[No Abstract] [Full Text] [Related]
16. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
[TBL] [Abstract][Full Text] [Related]
17. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
[TBL] [Abstract][Full Text] [Related]
18. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.
Patsatsi A; Kyriakou A; Pavlitou-Tsiontsi A; Giannakou A; Sotiriadis D
Clin Dev Immunol; 2012; 2012():854795. PubMed ID: 23227089
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
Charneux J; Lorin J; Vitry F; Antonicelli F; Reguiai Z; Barbe C; Tabary T; Grange F; Bernard P
Arch Dermatol; 2011 Mar; 147(3):286-91. PubMed ID: 21422334
[TBL] [Abstract][Full Text] [Related]
20. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
Skaria M; Jaunin F; Hunziker T; Riou S; Schumann H; Bruckner-Tuderman L; Hertl M; Bernard P; Saurat JH; Favre B; Borradori L
J Invest Dermatol; 2000 May; 114(5):998-1004. PubMed ID: 10771483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
